Skip to main content

CONTAMINATED BLOOD PRODUCTS PUBLIC INQUIRY

EDM (Early Day Motion) 1816A1: tabled on 04 November 2004

Tabled in the 2003-04 session.

This motion has been signed by 12 Members. It is an amendment to an existing motion.

As this motion is using historical data, we may not have the record of the original ordering, in which case signatories are listed alphabetically.

This is an amendment to an existing motion

This motion was originally tabled by Mrs Patsy Calton on 26 October 2004. This is amendment number 1.

View details of the original motion

Suggested amendment

Line 4, leave out from 'inquiry' to end and insert 'into the use of contaminated blood products in the treatment of haemophilia and in transfusions in the past; while recognising the progress made in the term of the present Labour government in allocating funds to provide non blood based recombinant clotting products for throughout the UK and a fund of approximately ú100 million to provide payments to all who are living with Hepatitis C, and urge the government to extend the payments to the families of those who have died as a result of contaminated blood products.'

Original motion text

That this House notes the severe illness and deaths of haemophiliacs and some partners from HIV and hepatitis C, caused by the use of contaminated blood products, and the potential for future deaths from vCJD; and supports the Haemophilia Society in its call for an independent public inquiry into the contamination of haemophilia treatment since the 1970s, in particular the failure to make the UK self-sufficient in blood products, the failure in some parts of the UK to make a timely switch to virally inactivated treatment when this became available from 1985 and the failure to make timely provision of genetically-engineered recombinant Factor VIII and IX for all haemophiliacs.